{"id":"palonosetron-dexamethasone-and-0-9-nacl","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1189679","moleculeType":"Small molecule","molecularWeight":"296.41"},"_fixedAt":"2026-03-30T12:00:12.943062","_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Palonosetron specifically targets 5-HT3 receptors in the central nervous system and gastrointestinal tract to prevent nausea and vomiting. Dexamethasone reduces inflammation and also acts as an antiemetic by modulating the release of inflammatory mediators and affecting the chemoreceptor trigger zone in the brain.","oneSentence":"Palonosetron blocks serotonin 5-HT3 receptors, while dexamethasone has anti-inflammatory and antiemetic effects, and 0.9% NaCl provides hydration and electrolyte balance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:30.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT04853147","phase":"PHASE3","title":"Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2021-04-27","conditions":"C.Surgical Procedure; Gastrointestinal","enrollment":1154},{"nctId":"NCT01111942","phase":"EARLY_PHASE1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2010-02","conditions":"Head and Neck Cancer","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2017 May","pmid":"31156929","title":"Compatibility of dexamethasone sodium phosphate with 5-HT(3) receptor antagonists in infusion solutions: a comprehensive study.","journal":"European journal of hospital pharmacy : science and practice"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["double therapy"],"phase":"phase_3","status":"active","brandName":"palonosetron, dexamethasone, and 0.9% NaCl","genericName":"palonosetron, dexamethasone, and 0.9% NaCl","companyName":"Sixth Affiliated Hospital, Sun Yat-sen University","companyId":"sixth-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palonosetron blocks serotonin 5-HT3 receptors, while dexamethasone has anti-inflammatory and antiemetic effects, and 0.9% NaCl provides hydration and electrolyte balance. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}